Evidence map›Paper›PMID 32582866›Full record

ArticleHepatoma research2020

Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series.

Cem Simsek, Amy Kim, Michelle Ma, Nilay Danis, Merve Gurakar, Andrew M Cameron, Benjamin Philosophe, Jacqueline Garonzik-Wang, Shane Ottmann, Ahmet Gurakar and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatoma research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review.Journal of clinical and translational hepatology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Cem SimsekJohns Hopkins University School of Medicine, Division of Gastroenterology and Hepatology-Transplant Hepatology, Baltimore, MD 21205, USA.
Amy KimJohns Hopkins University School of Medicine, Division of Gastroenterology and Hepatology-Transplant Hepatology, Baltimore, MD 21205, USA.
Michelle MaJohns Hopkins University School of Medicine, Division of Gastroenterology and Hepatology-Transplant Hepatology, Baltimore, MD 21205, USA.
Nilay DanisJohns Hopkins University School of Medicine, Division of Gastroenterology and Hepatology-Transplant Hepatology, Baltimore, MD 21205, USA.
Merve GurakarJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Andrew M CameronJohns Hopkins University School of Medicine, Division of Transplant Surgery, Baltimore, MD 21205, USA.
Benjamin PhilosopheJohns Hopkins University School of Medicine, Division of Transplant Surgery, Baltimore, MD 21205, USA.
Jacqueline Garonzik-WangJohns Hopkins University School of Medicine, Division of Transplant Surgery, Baltimore, MD 21205, USA.
Shane OttmannJohns Hopkins University School of Medicine, Division of Transplant Surgery, Baltimore, MD 21205, USA.
Ahmet GurakarJohns Hopkins University School of Medicine, Division of Gastroenterology and Hepatology-Transplant Hepatology, Baltimore, MD 21205, USA.
Behnam SaberiJohns Hopkins University School of Medicine, Division of Gastroenterology and Hepatology-Transplant Hepatology, Baltimore, MD 21205, USA.

Funding

Development of a Urine Test for the Early Detection of Liver CancerR44CA165312 · NCI · JBS SCIENCE, INC. · PI LIN, SELENA · 2013 to 2020
$4.9M
Pathway Specific Functional Biomarkers for the Early Detection of Liver CancerU01CA230690 · NCI · GEORGE WASHINGTON UNIVERSITY · PI MISHRA, LOPA, SHETTY, KIRTI · 2018 to 2022
$3.4M
NCI NIH HHS R44 CA165312NCI NIH HHS U01 CA230690
6 · The paper itself

Abstract

aimWe aimed to study the clinical and pathological characteristics of liver transplant recipients with hepatocellular carcinoma recurrence.

methodsWe reviewed the data for 26 patients who had tumor recurrence after deceased donor liver transplant for hepatocellular carcinoma at the Johns Hopkins Hospital from January 2005 to December 2015.

resultsIn total, 88% of recipients were males. The mean age was 59 years. On explant, poor differentiation was detected in 43%, while 73% had microvascular invasion. Overall, 62% were diagnosed to be outside of Milan criteria. Out of these, 15% met the criteria for downstaging. Twenty (77%) patients had pre-transplant alpha fetoprotein levels ≥ 20 ng/mL. In 54% of patients, the location of hepatocellular carcinoma (HCC) recurrence was extrahepatic, followed by intrahepatic in 31% and both intra- and extrahepatic in 15%. The post-transplant tumor recurrence was diagnosed at a mean of 427 days (range 34-1502). Fifty percent of HCC recurrences were diagnosed within one year following liver transplant. Twenty (77%) patients received treatment for their recurrent HCC: external radiation (

conclusionHCC recurrence after liver transplant is infrequent. More than fifty percent of HCC recurrences following liver transplant are extrahepatic. Despite better recipient selection for liver transplant, the curative options are limited in recurrent cases and associated with extremely poor outcomes.

Indexed as

Hepatocellular carcinomaliver resectionliver transplantlocoregional therapy

Identifiers

PMID32582866
PMCPMC7313412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.